Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843454 | 0.88 | KLK7 (0.45) | NPC1LMNANPSR1MEN1KMT2A | |
| SCHEMBL28194949 | 0.88 | KLK7 (0.45) | NPC1LMNANPSR1MEN1KMT2A | |
| SCHEMBL13997813 | 0.88 | KLK7 (0.45) | NPC1LMNANPSR1MEN1KMT2A | |
| SCHEMBL29997863 | 0.88 | KLK7 (0.45) | NPC1LMNANPSR1MEN1KMT2A | |
| SCHEMBL10132323 | 0.86 | NPSR1 (0.49) | NPC1LMNANPSR1MEN1KMT2A | |
| SCHEMBL25971634 | 0.86 | NPSR1 (0.49) | NPC1LMNANPSR1MEN1KMT2A | |
| SCHEMBL4143386 | 0.86 | GPR119 (0.47) | NPC1GPR119UCHL1HSD17B10 | |
| SCHEMBL10132539 | 0.86 | MAPT (0.45) | NPC1LMNANPSR1MEN1KMT2A | |
| SCHEMBL10132285 | 0.85 | ALDH1A1 (0.47) | NPC1LMNANPSR1MEN1KMT2A | |
| SCHEMBL10132244 | 0.85 | MEN1 (0.43) | NPC1LMNANPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329686-B2 | Isatin analogues and uses therefor | WASHINGTON UNIVERSITY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20090068105-A1 | ISATIN ANALOGUES AND USES THEREFOR | WASHINGTON UNIVERSITY IN ST. LOUIS | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068105-A1 | ISATIN ANALOGUES AND USES THEREFOR | CASP7, CASP3, HASPIN | NPC1 2112/4885LMNA 1076/4885NPSR1 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.